Low libido is one of the most common concerns we see at Vital Wellness Clinic. More than 50% of women who present to our clinic report reduced sexual desire, even when they describe:
- A strong emotional connection with their partner
- A healthy marriage or relationship
- Only mild to moderate stress levels
For many women, low libido can be frustrating and confusing—especially when lab work appears normal and lifestyle factors are well controlled.
When Testosterone Isn’t Enough
In some cases, women do benefit from testosterone replacement therapy (TRT), particularly when testosterone levels are low. However, a significant number of women do not experience meaningful improvement in libido with testosterone therapy alone.
This is because sexual desire is not driven solely by hormones. The brain plays a central role in sexual motivation, arousal, and responsiveness.
That’s where PT-141 becomes an important option.
What Is PT-141?
PT-141, also known as Bremelanotide, is a synthetic peptide that works directly on the brain, not on blood flow.
Unlike medications that focus on increasing circulation, PT-141 activates melanocortin receptors in the hypothalamus, the area of the brain responsible for sexual desire and arousal. This central mechanism makes it particularly helpful for women who:
- Have normal hormone levels
- Do not respond to testosterone therapy
- Experience low desire rather than purely physical arousal issues
Who Can Use PT-141?
PT-141 is FDA-approved for premenopausal women with hypoactive sexual desire disorder (HSDD) under the brand name Vyleesi.
In clinical practice, PT-141 may also be used off-label for:
- Perimenopausal and menopausal women
- Men with low sexual desire despite normal testosterone levels
- Patients with a strong neurologic or psychologic component to low libido
Off-label use is common in sexual and integrative medicine when clinically appropriate and supervised.
How PT-141 Is Administered
PT-141 can be administered in two ways:
- Subcutaneous injection (most common)
- Intranasal formulation (in select cases)
What to expect:
- Onset: 30–60 minutes
- Duration: Up to 2–3 days
- Use: As needed only — not recommended for daily use
Dosing and frequency are individualized based on response and tolerance.
Potential Benefits
Patients may experience:
- Increased sexual desire
- Improved arousal and responsiveness
- Enhanced intimacy and satisfaction
- Benefits even when testosterone levels are normal
Because PT-141 acts centrally, it can be used alone or alongside hormone optimization.
Side Effects & Safety Considerations
The most common side effect is flushing, which typically occurs 15–20 minutes after injection and resolves on its own.
Other reported side effects may include:
- Nausea
- Headaches
- Temporary increase in blood pressure
- Mild fatigue
Some patients also notice skin darkening or bronzing, as PT-141 is derived from melanocyte-stimulating pathways.
PT-141 should always be prescribed and monitored by a qualified medical provider, especially in patients with cardiovascular risk factors.
Cost & Insurance Considerations
The FDA-approved brand Vyleesi is often not covered by insurance and can be expensive for many patients. Because of this, some patients explore alternative medically supervised options based on individual circumstances and availability.
The Vital Wellness Approach
At Vital Wellness Clinic, we recognize that sexual health is multifactorial. Low libido may be influenced by:
- Neurochemical signaling
- Hormonal balance
- Stress and sleep quality
- Metabolic health
- Emotional and relational factors
PT-141 is never viewed as a stand-alone fix, but rather as part of a personalized, comprehensive treatment plan.
For women who feel dismissed or frustrated when hormones alone don’t restore desire, PT-141 offers a science-backed, brain-based option that addresses the neurologic side of libido. When used thoughtfully and medically supervised, it can be a valuable tool in restoring sexual wellness and quality of life. Contact us today to learn more.
References
- Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. Obstetrics & Gynecology. 2019.
https://journals.lww.com/greenjournal/Fulltext/2019/02000/Bremelanotide_for_the_Treatment_of.14.aspx - FDA Drug Approval: Vyleesi (bremelanotide).
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-vyleesi-hypoactive-sexual-desire-disorder-premenopausal-women - Clayton AH, et al. Evaluation of the efficacy and safety of bremelanotide. Journal of Sexual Medicine.
https://academic.oup.com/jsm/article/16/10/1540/5612953
Wessells H, et al. Melanocortin receptor agonists and sexual function. Nature Reviews Urology.
https://www.nature.com/articles/nrurol.2011.55